EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access

Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease

Scott M Matson, Misbah Baqir, Teng Moua, Michael Marll, Jessica Kent, Nicholas S Iannazzo, Ryan D Boente, John M Donatelli, Junqiang Dai, Francisco J Diaz, M Kristen Demoruelle, Mark B Hamblin und 5 weitere

Chest · 2023-04 · 163 (4) · 861-869

DOI: 10.1016/j.chest.2022.11.035 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Chest, 2023-04. Verfasst von Scott M Matson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS. Electronic address: smatson@kumc.edu. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppression to treat RA-associated ILD, despite being widely used in clinical practice. RESEARCH QUESTION: How does immunosuppression impact pulmonary function trajectory in a multisite retrospective cohort of patients with RA-associated ILD? STUDY DESIGN AND METHODS: Patients with RA who started treatment for ILD with mycophenolate, azathioprine, or rituximab were identified retrospectively from five ILD centers. Change in lung function before and after treatment was analyzed using a linear spline mixed-effect model with random intercept. Prespecified secondary analyses examined the impact of radiologic pattern of ILD (ie, usual interstitial pneumonia [UIP] vs non-UIP) on treatment trajectory. RESULTS: Two hundred twelve patients were included in the analysis: 92 patients (43.4%) were treated with azathioprine, 77 patients (36.3%) were treated with mycophenolate mofetil, and 43 patients (20.3%) were treated with rituximab. In the combined analysis of all three agents, an improvement in FVC % predicted was found after 12 months of treatment compared with the potential 12-month response without treatment (+3.90%; P ≤ .001; 95% CI, 1.95-5.84). Diffusing capacity of the lungs for carbon monoxide (Dlco) % predicted also improved at 12 months (+4.53%; P ≤ .001; 95% CI, 2.12-6.94). Neither the UIP pattern of ILD nor choice of immunosuppressive agent significantly impacted the pulmonary function trajectory on immunosuppression. INTERPRETATION: Immunosuppression was associated with an improved trajectory in FVC and Dlco compared with the pretreatment pulmonary function trajectory. Prospective, randomized trials are required to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidIdiopathic Pulmonary FibrosisLung Diseases, InterstitialHumansAzathioprineImmunosuppression TherapyImmunosuppressive AgentsLungProspective StudiesRetrospective StudiesRituximabTreatment OutcomeVital Capacity

Stichwörter der Autor:innen

azathioprineinterstitial lung diseasemycophenolaterheumatoid arthritisrituximab

Substanzen

AzathioprineImmunosuppressive AgentsRituximab

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS. Electronic address: smatson@kumc.edu.
  • Division of Pulmonary, Critical Care Medicine, Mayo Clinic, Rochester, MN.
  • Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
  • Department of Internal Medicine, Baylor University Medical Center, Dallas, TX.
  • Department of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN.

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Matson, S. M., Baqir, M., Moua, T., Marll, M., Kent, J., Iannazzo, N. S., Boente, R. D., Donatelli, J. M., Dai, J., Diaz, F. J., Demoruelle, M. K., Hamblin, M. B., Mathai, S. K., Ryu, J. H., Pope, K., Walker, C. M., & Lee, J. S. (2023). Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 163(4), 861-869. https://doi.org/10.1016/j.chest.2022.11.035

Vancouver

Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, et al. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest. 2023;163(4):861-869. doi:10.1016/j.chest.2022.11.035

BibTeX
@article{Matson2023,
  author = {Matson, Scott M and Baqir, Misbah and Moua, Teng and Marll, Michael and Kent, Jessica and Iannazzo, Nicholas S and Boente, Ryan D and Donatelli, John M and Dai, Junqiang and Diaz, Francisco J and Demoruelle, M Kristen and Hamblin, Mark B and Mathai, Susan K and Ryu, Jay H and Pope, Kristen and Walker, Christopher M and Lee, Joyce S},
  title = {Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease},
  journal = {Chest},
  year = {2023},
  volume = {163},
  number = {4},
  pages = {861--869},
  doi = {10.1016/j.chest.2022.11.035}
}
Kostenlos starten →